Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

195 results about "Anti sense" patented technology

Plants and processes for obtaining them

Plants, particularly cereal plants, which have improved ability to synthesise starch at elevated or lowered temperatures and / or to synthesise starch with an altered fine structure are produced by inserting into the genome of the plant (i) a gene(s) encoding a form of an enzyme of the starch or glycogen biosynthetic pathway, particularly soluble starch synthase and / or branching enzyme and / or glycogen synthase, which display an activity which continues to increase over a temperature range over which the activity would normally be expected to decrease, and / or (ii) a gene(s) encoding sense and anti-sense constructs of enzymes of the starch biosynthetic pathway, particularly soluble starch synthase and / or branching enzyme and / or glycogen synthase, which alters the natural ratios of expression of the said enzymes or inserts enzymes with special structural characteristics which alter the natural branching pattern in starch.
Owner:ZENECA LTD

Reagents and methods for direct labeling of nucleotides

The present invention provides systems and methods for production of activatable diazo-derivatives for use in labeling nucleotides. Labeling nucleotides is accomplished by contacting a stable hydrazide derivative of a detectable moiety with an activating polymer reagent which is used to directly label the nucleotide sample. Labeling occurs on the phosphate backbone of the nucleotide which does not perturb hybridization of the labeled nucleotide with its anti-sense strand. Since the method involves direct labeling, all types of nucleotides can be labeled without prior amplification or alteration.
Owner:MARKER GENE TECH

RNA interference preparation used for treating viral hepatitis B

The invention discloses a RNA interference preparation used for treating viral hepatitis B. The RNA interference preparation comprises one or more sense strands and one or more antisense strands, wherein one or more polynucleotide strands are complementary with one or more regions of HBV RNA. An iNA is an iNAs having a structure of double stands. The double strands have structures of linear, loop, similar-loop, hairpin-type, stem-loop, unidirectional or bidirectional. The RNA interference preparation provided by the invention can be used for treating viral hepatitis B.
Owner:厦门成朴希晟股权投资合伙企业(有限合伙)

Potent inhibition of influenza virus by specifically designed short interfering RNA

ActiveUS7199109B2BiocideSugar derivativesInfluenza virus nucleoproteinEukaryotic plasmids
This patent application discloses siRNA sequences against the constant region of the influenza virus nucleoprotein gene comprising:Sense strand:5′ UGAAGGAUCUUAUUUCUUCdTdT 3′(SEQ ID NO: 1)Anti sense strand:3′ dTdTACUUCCUAGAAUAAAGAAG 5′(SEQ ID NO: 2)Sense strand:5′ UGAAGGAUCUUAUUUCUUCGGdTdT 3′(SEQ ID NO: 3)Anti sense strand:3′ dTdTACUUCCUAGAAUAAAGAAGCC 5′(SEQ ID NO: 4)Sense strand:5′ GGAUCUUAUUUCUUCGGAGACdTdT 3′(SEQ ID NO: 5)Anti sense strand:3′ dTdTCCUAGAAUAAAGAAGCCUCUG 5′(SEQ ID NO: 6)said sequences being inhibitory against influenza virus in animals including humans. The invention further includes one or more of said siRNA sequences in the form of an aqueous suspension suitable for nasal inhalation. Still further, the invention includes one or more of said siRNA sequences in the form of a plasmid expressing intracellularly in animals including humans. In another aspect, the invention includes one or more of said siRNA sequences in the form of an AAV vector adapted to express intercellularly and establish a permanent inhibitory effect against influenza virus by integrating to the cellular chromosome of animals including humans. The invention also includes the administration to an animal including humans, in a therapeutically effective amount, at least one of said siRNA sequences.
Owner:CALIFORNIA POLYTECHNIC STATE UNIVERSITY

Plant pyruvate dehydrogenase kinase gene

The present invention relates to the isolation, purification, characterization and use of a mitochondrial pyruvate dehydrogenase kinase (PDHK) gene [SEQ ID NO:1](pYA5; ATCC No 209562) from the Brassicaceae (specifically Arabidopsis thaliana). The invention includes isolated and purified DNA of the stated sequence and relates to methods of regulating fatty acid synthesis, seed oil content, seed size/weight, flowering time, vegetative growth, respiration rate and generation time using the gene and to tissues and plants transformed with the gene. The invention also relates to transgenic plants, plant tissues and plant seeds having a genome containing an introduced DNA sequence of SEQ ID NO:1; or a part of SEQ ID NO:1 characterized in that said sequence has been introduced into an antisense or sense orientation, and a method of producing such plants and plant seeds. The invention also relates to substantially homologous DNA sequences from plants encoding proteins with deduced amino acid sequences of 25% or greater identity, and 50% or greater similarity, isolated and/or characterized by known methods using the sequence information of SEQ ID NO:1, and to parts of reduced length that are still able to function as inhibitors of gene expression by use in an anti-sense, co-suppression or other gene silencing technologies.
Owner:NAT RES COUNCIL OF CANADA

Small interfering nucleic acid and medical composite and pharmaceutical applications of nucleic acid

The invention provides small interfering nucleic acid of which sequences are as follows: the sequence of the sense strand is 5'-CCUUGAGGCAUACUUCAAAdTdT-3' and the sequence of the anti-sense strand is 5'-UUUGAAGUAUGCCUCAAGGdTdT-3'. The small interfering nucleic acid has the modifications shown from A1 to A5. The invention also provides a medical composite used for preventing and / or curing hepatitis B and the medical composite contains the small interfering nucleic acid provided by the invention and uses the nucleic acid as the active component. The invention also provides the applications of the small interfering nucleic acid in preparations of medicines for preventing and / or curing hepatitis B. Through the specific modifications, the aim of increasing the serum stability of the small interfering nucleic acid can be achieved under the condition of only introducing a small amount of modifications, thus the potential cytotoxicity of the modified small interfering nucleic acid molecule can be reduced and the influence on the biological activity can be lowered.
Owner:SUZHOU RIBO LIFE SCIENCE CO LTD

Method for constructing tandem expression small interfering RNA recombinant lentiviral vector

InactiveCN101684478APrevent or delay escapeSilent and stableFermentationGenetic engineeringChemical synthesisEnzyme digestion
The invention discloses a method for constructing a tandem expression small interfering RNA recombinant lentiviral vector. The method comprises the following steps of: (1) constructing the siRNA recombinant lentiviral vector with single target spot: a, chemically synthesizing an oligonucleotide chain; b, annealing a sense chain and an anti-sense chain; and c, connecting an annealing fragment to the vector; (2) constructing the siRNA recombinant lentiviral vector with double target spots: a, amplifying a U6/H1-siRNA expression frame from the siRNA recombinant lentiviral vector with single target spot by utilizing the PCR; b, connecting the expression frame to the siRNA recombinant lentiviral vector with single target spot undergoing enzyme digestion by the XhoI; and c, performing the enzymedigestion, identification and screening of the clone forwardly inserted in the expression frame; and (3) constructing the siRNA recombinant lentiviral vector with multiple target points in tandem connection: inserting the U6/H1-siRNA expression frame in the siRNA recombinant lentiviral vector with double target spots to construct the siRNA recombinant lentiviral vector with triple target spots, and obtaining the siRNA recombinant lentiviral vector with multiple target points in tandem connection by repeating the step. The construction method is suitably used for the expression of the siRNA with multiple target genes as well as the research on the multiple target genes which are silent for a long time.
Owner:WUHAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products